New combo aims to stop lymphoma from spreading to the brain

NCT ID NCT05257018

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a chemotherapy regimen (R-CDOP) plus a drug injected into the spine (intrathecal methotrexate) in 83 adults with untreated diffuse large B-cell lymphoma at high risk of spreading to the brain. The goal is to see if this combination lowers the chance of central nervous system relapse within two years. Participants must be 18-75 and have specific high-risk features.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Cancer Hospital affilicaited to Xinjiang Medical University
NOT_YET_RECRUITING

Ürümqi, Xinjiang, China
Dongmei Ji
RECRUITING

Shanghai, Shanghai Municipality, 021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.